^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOLH1 overexpression

    i
    Other names: FOLH1, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, Folate hydrolase 1, prostate-specific membrane antigen
    Entrez ID:
    2346
    Related biomarkers:
    Expression
    1year
    [68Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma. (PubMed, Eur J Nucl Med Mol Imaging)
    Utilizing a hybrid PET/MRI system to combine [68Ga]Ga-PSMA-617 PET/MRI with ceMRI is a promising one-stop solution for the accurate diagnosis of HCC.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression
    1year
    Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma. (PubMed, Front Oncol)
    The results suggest that a theranostic strategy targeting PSMA, employing PET and α-emitting radiopharmaceuticals, enabled tumor growth control and enhanced survival in a relevant immunocompetent murine model of RCC. These studies provide the rationale for clinical studies of PSMA-targeted theranostic agents in patients with RCC.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression
    over1year
    Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC) (ESMO 2024)
    This is the largest combined clinicogenomic analysis of FOLH1 expression in PC. Tumors with high FOLH1 are molecularly and immunologically distinct, providing insights for distinct therapeutic strategies in this group.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • AR (Androgen receptor) • ASXL1 (ASXL Transcriptional Regulator 1) • LAG3 (Lymphocyte Activating 3) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • FOLH1 (Folate hydrolase 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    |
    PD-L1 expression • LAG3 expression • AR splice variant 7 • FOLH1 expression • FOLH1 overexpression • PD-L2 expression
    |
    VENTANA PD-L1 (SP142) Assay • MI Tumor Seek™
    over1year
    Prostate Specific Membrane Antigen Expression in a Syngeneic Breast Cancer Mouse Model. (PubMed, Mol Imaging Biol)
    The selective uptake of PSMA-1-Pc413 in these cancer tissues as well as the characterization and validation of PSMA expression on neovasculature in this syngeneic 4T1 model emphasizes their potential for advancements in targeted therapies and imaging techniques for BCa. PSMA holds great promise as an oncogenic target for BCa and its associated metastases.
    Preclinical • Journal
    |
    FOLH1 (Folate hydrolase 1) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    FOLH1 expression • CD31 expression • FOLH1 overexpression
    over1year
    Prostate-specific Membrane Antigen (PSMA) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules (ENDO 2024)
    Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • FOLH1 (Folate hydrolase 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)
    |
    RET fusion • ALK fusion • FOLH1 expression • FOLH1 overexpression
    |
    Afirma® Genomic Sequencing Classifier
    over1year
    Prostate-specific Membrane Antigen (PSMA) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules (ENDO 2024)
    Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • FOLH1 (Folate hydrolase 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)
    |
    RET fusion • ALK fusion • FOLH1 expression • FOLH1 overexpression
    |
    Afirma® Genomic Sequencing Classifier
    over1year
    PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI. (PubMed, Radiol Med)
    Increased prostatic PSMA uptake on PET might be estimated based on T2 MRI alone. Further investigation with larger cohorts and external validation is needed to assess whether PSMA uptake can be predicted accurately enough to help in the interpretation of mpMRI.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression • FOLH1 positive
    over1year
    Intramuscular Granular Cell Tumor Detected on 68Ga-PSMA PET/CT. (PubMed, Clin Nucl Med)
    After several years of clinical experience with PSMA tracers, the specificity is satisfactory; however, concerns about the specificity are raising day by day due to the newly laid out nonprostatic malignant and benign lesions with high PSMA expression. Herein, we present an incidental 68Ga-PSMA uptake in an intramuscular granular cell tumor.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression
    over1year
    Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. (PubMed, Theranostics)
    The present preclinical and clinical data demonstrate that the combination of EBRT with dose escalation by PSMA-RLT improves tumor control and potentially prolongs survival. This may pave the way for further clinical investigations of this approach to explore the curative potential of the combination therapy.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    over1year
    Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas. (PubMed, J Nucl Med)
    Interestingly, FOLH1 expression was associated with relapse-free and distant metastasis-free survival in patients with BLBC. The BLBC subtype exhibited frequent amplification and overexpression of PSMA, supporting the exploration of PSMA-targeting radiopharmaceuticals in this aggressive breast cancer subtype.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • FOLH1 (Folate hydrolase 1)
    |
    EGFR positive • FOLH1 expression • FOLH1 overexpression • PGR expression
    almost2years
    Quadruplet Therapy in De Novo High-Volume Mixed Neuroendocrine Prostate Cancer Using 177Lu-PSMA: A Case Report. (PubMed, Clin Nucl Med)
    The patient responded well to this treatment, but recurrence was ultimately inevitable. This case represents a typical example of mixed neuroendocrine prostate carcinoma and highlights its resistant phenotype in response to quadruplet therapy.
    Journal
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression